Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | SPR | P35270 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12499298 | 0.98 | ALDH1A1 (0.35) | TSHRNFKB1CYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL3469463 | 0.93 | TSHR (0.35) | TSHRNFKB1CYP2C19KDM5AKDM4C | |
| Hydrochloric Acid SCHEMBL29089994 | 0.91 | TSHR (0.34) | TSHRNFKB1CYP2C19KDM5AKDM4C | |
| SCHEMBL21296526 | 0.84 | — | — | |
| SCHEMBL4020424 | 0.82 | ALDH1A1 (0.37) | TSHRNFKB1CYP2C19ALDH1A1KDM5A | |
| SCHEMBL18711702 | 0.80 | TSHR (0.35) | TSHRNFKB1CYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL15319783 | 0.80 | TSHR (0.39) | TSHRNFKB1CYP2C19ALDH1A1KDM5A | |
| SCHEMBL10590189 | 0.78 | TSHR (0.34) | TSHRNFKB1CYP2C19ALDH1A1KDM5A | |
| SCHEMBL20707613 | 0.78 | ALDH1A1 (0.34) | TSHRNFKB1CYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL9059659 | 0.78 | F2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108698992-B | 2-cyanoisoindoline derivatives for the treatment of cancer | 特殊治疗有限公司 | 2022-04-19 | — | — | CN | claimed |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-16 | — | — | US | claimed |
| US-20180092924-A1 | NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2018-04-05 | — | — | US | claimed |
| EP-3027604-A2 | NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS | Zenith Epigenetics Corp. (CA) | 2016-06-08 | — | — | EP | claimed |
| EP-2874632-A2 | NOVEL TRIAZINE COMPOUNDS | Sphaera Pharma Pte. Ltd (SG) | 2015-05-27 | — | — | EP | claimed |
| US-8957081-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2015-02-17 | — | — | US | claimed |
| WO-2014016849-A9 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2014-03-13 | — | — | WO | claimed |
| WO-2014016849-A2 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PVT. LTD. (SG) | 2014-01-30 | — | — | WO | claimed |
| WO-2013175281-A1 | USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) PROTEINS | RVX THERAPEUTICS INC. (CA) | 2013-11-28 | — | — | WO | claimed |
| CN-103214376-A | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH | 2013-07-24 | — | — | CN | claimed |
| CN-103183630-A | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH | 2013-07-03 | — | — | CN | claimed |
| US-20130005748-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2013-01-03 | — | — | US | claimed |
| CN-102046595-A | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH | 2011-05-04 | — | — | CN | claimed |
| JP-2007523072-A | — | — | 2007-08-16 | — | — | JP | claimed |
| EP-1713781-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | claimed |
| WO-2005075439-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | claimed |
| US-20260138951-A1 | TREATING PKU WITH SPIRO-SUBSTITUTED AND OTHER PIPERIDINE INHIBITORS OF SLC6A19 FUNCTION | JNANA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2006021656-A2 | AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF AS MELANOCORTIN RECEPTOR AGONISTS | SANOFI-AVENTIS (FR) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005075439-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138951-A1 | TREATING PKU WITH SPIRO-SUBSTITUTED AND OTHER PIPERIDINE INHIBITORS OF SLC6A19 FUNCTION | SLC6A19, SLC6A9, SLC2A9 | TSHR 1620/4885NFKB1 4521/4885CYP2C19 177/4885 |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | USP7, USP47, USP2 | TSHR 4510/4885NFKB1 1121/4885CYP2C19 2893/4885 |
| US-20180092924-A1 | NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRDT | TSHR 3605/4885NFKB1 1010/4885CYP2C19 4755/4885 |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | TSHR 2535/4885NFKB1 2533/4885CYP2C19 2370/4885 |
| US-20130005748-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | TSHR 1191/4885NFKB1 1275/4885CYP2C19 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.